Search global stocks & ETFs...Ctrl K
Learn Mode
TGTX
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
4.16
Good
Valuation Score
Key Score
2.00
Bad
Management
1.00
Very Bad
Growth
5.00
Very Good
Profitability
5.00
Very Good
Fin. Health
4.00
Good
Dividends
--
--
Analyst
4.00
Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$56.22
Baseline
High
$73.50
▲
30.74%
Avg
$49.47
▼
-12.01%
Low
$17.17
▼
-69.46%
Analyst Ratings based on 15 Analysts
Strong Buy
320%
Buy
960%
Hold
213%
Sell
107%
Strong Sell
000%
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. The company is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. The company is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The firm is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.Read More